Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Oncogene. 2021 Sep 29;40(45):6354–6368. doi: 10.1038/s41388-021-02009-8

Figure 7. Pituitary adenomas from pituitary-specific Aip-knockout mice or from human patients have overexpression of the RET/GDNF survival pathway.

Figure 7

Pituitary extracts from15-month old Aip Flox/Flox;Hesx1 Cre/+ knockout mice compared to AipFlox/Flox;Hesx1+/+ control mice. B) Increased levels of GDNF, phospho-AKT and phospho-mTOR and reduced expression of phospho-p53 and AIP are found in mutant animals. C) Expression of the CDKN2A probe set, including three probes, in AIP-FIPA pituitary adenomas compared to sporadic pituitary adenomas, retrieved from ReGEO GSE63357, a study using the using the Affymetrix HG-U133 Plus 2.0 array. Only 209644_x_at includes oligos specific for the CDKN2A-ARF specific Exon 1, while the other probes contain oligos specific for the other protein isoform CDKN2A-p16 specific Exon 1 (21156_at), or the common Exon 3 (207039_at). D) Immunohistochemistry comparing somatotroph macroadenomas from sporadic (Sp GH) or AIP-FIPA tumours (AIP+). E) Representative stainings for RET (total RET HPA008356), GDNF and GFRα1. Sections were counterstained with haematoxylin. F) Corresponding fields within the same sample, showing heterogeneity of GDNF staining compared to GH.

(N=3; Mann-Whitney, * p<0.05; numbers, when p is non-significant but approximates to significant levels)